Physician profile
Muhammad Khalid
NPI 1851829337
$875.64
in general payments reported to CMS, 2019-2025
11 companies · $577 in 2025
The $577 reported for 2025 was more than what 91% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $122 · 2023: $22.44 · 2024: $154 · 2025: $577.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $753.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $753.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $315.53 | 2024-2025 | Watchman, Watchman Flx, General - Brady |
| Astrazeneca Pharmaceuticals Lp | $153.03 | 2020-2025 | Lokelma, Farxiga |
| Novo Nordisk INC | $137.68 | 2024-2025 | Wegovy |
| Cvrx, INC. | $51.18 | 2025 | Barostim Neo System |
| Kestra Medical Technology Services, INC. | $47.01 | 2025 | Assure Wcd |
| E.R. Squibb & Sons, L.L.C. | $37.43 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $35.29 | 2025 | Uptravi |
| Amgen INC. | $32.24 | 2024 | Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $28.82 | 2025 | |
| Abbvie INC. | $22.44 | 2023 | |
| Terumo Medical Corporation | $14.99 | 2024 | Metacross Otw, Glidesheath Slender, Optitorque |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Khalid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.